The initial phase of the contract is believed to be worth $15m.
Paragon will develop a large-scale process suitable for cGMP manufacturing, under the contract.
Previously in October 2010, the US Army awarded a contract to Paragon which involves process development and scale-up production to support the efficacy and potency of filovirus vaccine candidates against deadly Ebola and Marburg viruses.
Paragon Bioservices is a contract research and GMP manufacturing organization with an emphasis on the development and manufacturing of biopharmaceuticals for research or clinical trials.